CASE PRESENTATION {#s1}
=================

In February 2015, a 42-year-old German male presented to the emergency department of the University Medical Centre in Hamburg, Germany with a 6-day history of fever up to 40°C, arthralgia, and retro-orbital pain. The day before presentation, he had returned from a 10-week trip to Thailand, where he had spent 2 months on Little Koh Chang, an island in the Andaman Sea in the Ranong Province. At the end of his trip, he spent 5 days in Hua Hin, a town at the Gulf of Thailand in the Prachuap Khiri Khan Province, and 5 days in Bangkok. He had not taken antimalarial chemoprophylaxis while being in Thailand.

There was no past medical history of note. On clinical examination, a temperature of 39.1°C, blood pressure of 156/80 mmHg, and a pulse of 106/minute were noted. The respiratory rate was recorded at 16 breaths/minute with an oxygen saturation of 95% on room air. The full blood count showed a thrombocytopenia of 81 × 10^9^/L and was otherwise normal; the C-reactive protein was 55 mg/L (reference range up to 5 mg/L). The liver enzymes were slightly elevated with an aspartate aminotransferase of 62 U/L (reference range, 10--50 U/L) and an alanine aminotransferase of 106 U/L (reference range, 10--50 U/L). The bilirubin was 0.5 mg/dL (reference range, \<1.2 mg/dL). Rapid diagnostic tests for malaria (Alere BinaxNOW, which detects the *Plasmodium falciparum*-specific Histidine-rich Protein II and the panmalarial Aldolase) and dengue fever gave negative results. However, a thick blood film showed plasmodia trophozoites at a density of 920/µL. On thin film, the microscopists on duty were unable to differentiate the *Plasmodium* species in the acute setting. Based on the negative result of the rapid-diagnostic test, a nonfalciparum malaria was suspected. The patient was admitted to the infectious disease ward. Treatment was started with atovaquone/proguanil 250/100 mg 4 tablets daily over 3 days. The patient rapidly recovered and was discharged 4 days after admission. For further parasite differentiation, malaria microscopy was repeated by the head parasitologist. After intense reading of the Giemsa-stained thin blood film, 2 parasite-infected erythrocytes were identified with morphological characteristics compatible with *Plasmodium malariae* or *P knowlesi* infection (Figure [1](#OFW039F1){ref-type="fig"}). Subsequently, species-specific polymerase chain reactions (PCRs) for the 5 human plasmodia species confirmed the presence of a monoinfection with *P knowlesi* \[[@OFW039C1], [@OFW039C2]\]. Figure 1.*Plasmodium knowlesi* trophozoites in the thin blood film. Shown are 2 microscopic images of a Giemsa-stained thin blood film of the patient, each containing a parasite-infected erythrocyte: (A) young trophozoite (ring form); (B) late trophozoite (band form).

DISCUSSION {#s2}
==========

*Plasmodium knowlesi* was first described in detail in 1932 by Biraj Das Gupta and Robert Knowles in Kalkutta as malaria of macaques \[[@OFW039C3]\]. *Plasmodium knowlesi* gained recognition as the fifth human malaria parasite in 2004, when Singh et al \[[@OFW039C4]\] discovered that 58% of microscopically diagnosed malaria patients in the Kapit Division, Sarawak, Borneo, Malaysia were positive for *P knowlesi* by PCR.

So far, the vast majority of *P knowlesi* patients have been diagnosed in Sabah and Sarawak, Borneo, Malaysia. Increasing incidences of *P knowlesi* malaria have been reported from Sabah and Sarawak in the last few years \[[@OFW039C5]--[@OFW039C7]\]. *Plasmodium knowlesi* infections have also been identified in Thailand, Vietnam, Singapore, Indonesia, Cambodia, Myanmar, and the Philippines \[[@OFW039C8], [@OFW039C9]\]. Travelers returning from Southeast Asia with imported *P knowlesi* malaria have occasionally been reported from nonendemic countries including the United Kingdome, Australia, Japan, Sweden, and Germany \[[@OFW039C3], [@OFW039C10]--[@OFW039C13]\]. Vicinity to natural forest areas is the main risk factor for contracting *P knowlesi* infection. Forests are the natural habitat of the natural hosts of *P knowlesi*, the long- and pig-tailed macaques \[[@OFW039C14]\]. Most patients with documented *P knowlesi* malaria lived in or at the fringe of forestry areas \[[@OFW039C3]\]. Although our patient had not specifically visited a forest or national park, he stayed close to forestry areas on Little Koh Chang and participated in a rafting tour close to Hua Hin as potential exposures. From both areas, the Ranong and Prachuap Khiri Khan provinces, *P knowlesi* infections in humans have been repeatedly reported \[[@OFW039C13], [@OFW039C15]--[@OFW039C18]\]. The short time duration between the rafting tour and development of fever (4 days) make an infection at Little Koh Chang more likely, but short incubation periods with a minimum of 3 days have been observed with *P knowlesi* \[[@OFW039C19]\].

*Plasmodium knowlesi* presents several diagnostic challenges. *Plasmodium knowlesi* can be detected by rapid diagnostic tests targeting panmalarial *Plasmodium* lactate dehydrogenase (pLDH), *Plasmodium vivax*-specific pLDH, *P falciparum*-specific pLDH, or panmalaria Aldolase, but sensitivities are low \[[@OFW039C14], [@OFW039C20], [@OFW039C21]\]. In particular, in infections with low parasitemia, rapid diagnostic tests often fail to diagnose an acute *P knowlesi* malaria, as seen with our patient \[[@OFW039C20]\]. Therefore, diagnosis of infection relies primarily on microscopy of blood films, which requires highly trained microscopists. However, even in the hands of an experienced microscopist, *P knowlesi* can be easily misdiagnosed as *Plasmodium malariae* due to morphological similarity of the 2 parasite species. Molecular genetic analysis of malaria patients in Sabah, Borneo determined that up to 83% of malaria patients microscopically diagnosed with *P malariae* malaria were indeed infected with *P knowlesi* \[[@OFW039C22]\]. Polymerase chain reaction is the most reliable method to distinguish *P knowlesi* from other species, but it is usually not available in an acute setting. This diagnostic challenge has important consequences for patient management. Although *P malariae* malaria rarely causes complications, being termed "benign quartan malaria", *P knowlesi* infection can potentially be fatal because the parasite is able to rapidly develop high parasitemia due to its short erythrocytic cycle of only 24 hours. Severe courses of *P knowlesi* malaria are observed in approximately 10% of hospitalized patients and include respiratory distress syndrome or renal failure \[[@OFW039C6], [@OFW039C23], [@OFW039C24]\].

Several treatment options exist for uncomplicated *P knowlesi* infection. To date, chloroquine remains widely used for the treatment of confirmed *P knowlesi* infection \[[@OFW039C8], [@OFW039C25]\]. However, due to the increasing chloroquine resistance rates among *P falciparum* in Asia, chloroquine should only been used when a *P falciparum* infection or coinfection can be safely excluded \[[@OFW039C8]\]. Alternatively, artemisinin-combination drugs are increasingly used as first choice and offer the advantage to cover all malaria species \[[@OFW039C8], [@OFW039C26]--[@OFW039C28]\]. Furthermore, the first randomized controlled trial for the treatment of *P knowlesi* malaria, which compared treatment with chloroquine to mefloquine-artesunate, showed a faster parasite clearance when using mefloquine-artesunate \[[@OFW039C29]\]. Other treatment options for *P knowlesi* include atovaquone/proguanil, which also treats all malaria species \[[@OFW039C27]\]. Severe *P knowlesi* infection should be treated with parenteral artesunate \[[@OFW039C8], [@OFW039C28]\].

CONCLUSIONS {#s3}
===========

Our case highlights the need to consider *P knowlesi* malaria in febrile patients residing in or traveling from Southeast Asia in whom rapid antigen test for malaria is negative and microscopic species definition of plasmodia is inconclusive or a nonfalciparum species is suspected. Polymerase chain reaction assays remain an important tool to reliably identify *P knowlesi*.
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